Neovasc Inc (US) (NASDAQ: NVCN) is one of 80 publicly-traded companies in the “Advanced Medical Equipment & Technology” industry, but how does it contrast to its peers? We will compare Neovasc Inc (US) to related businesses based on the strength of its risk, valuation, institutional ownership, analyst recommendations, dividends, profitability and earnings.

Valuation & Earnings

This table compares Neovasc Inc (US) and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Neovasc Inc (US) $9.51 million -$86.49 million 2.44
Neovasc Inc (US) Competitors $2.14 billion $234.27 million -37.81

Neovasc Inc (US)’s peers have higher revenue and earnings than Neovasc Inc (US). Neovasc Inc (US) is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.


This table compares Neovasc Inc (US) and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Neovasc Inc (US) 268.35% -85.81% 23.39%
Neovasc Inc (US) Competitors -315.51% -23.26% -9.57%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Neovasc Inc (US) and its peers, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neovasc Inc (US) 0 0 3 0 3.00
Neovasc Inc (US) Competitors 276 1909 3412 109 2.59

Neovasc Inc (US) currently has a consensus target price of $6.33, suggesting a potential upside of 859.60%. As a group, “Advanced Medical Equipment & Technology” companies have a potential upside of 0.20%. Given Neovasc Inc (US)’s stronger consensus rating and higher possible upside, equities analysts plainly believe Neovasc Inc (US) is more favorable than its peers.

Institutional and Insider Ownership

19.2% of Neovasc Inc (US) shares are held by institutional investors. Comparatively, 51.8% of shares of all “Advanced Medical Equipment & Technology” companies are held by institutional investors. 18.4% of shares of all “Advanced Medical Equipment & Technology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk & Volatility

Neovasc Inc (US) has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500. Comparatively, Neovasc Inc (US)’s peers have a beta of 1.24, meaning that their average share price is 24% more volatile than the S&P 500.


Neovasc Inc (US) beats its peers on 7 of the 13 factors compared.

Neovasc Inc (US) Company Profile

Neovasc Inc. (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company’s segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products. The Tiara is in preclinical/early clinical stage development to provide a minimally invasive transcatheter device for patients experiencing mitral regurgitation (MR) as a result of mitral heart valve disease. The Reducer is an hourglass-shaped, balloon-expandable, stainless steel, bare metal device, which is implanted in the coronary sinus, creating a restriction in venous outflow from the myocardium (the muscular layer of the heart wall). Neovasc produces Peripatch, a biological tissue product that is manufactured from pericardium.

Receive News & Ratings for Neovasc Inc (US) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc Inc (US) and related companies with's FREE daily email newsletter.